MedDataX Logo

Molecular Mechanisms Underpinning Sarcopenic Obesity

NCT ID: NCT06120647

Last Updated: 2023-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-28

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenic Obesity Obesity Sarcopenia Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sarcopenic obesity

Age: 70-80 years Men, ALM/W \< 25.7 %, body fat % \> 35 Women, ALM/W \< 19.7 %, body fat % \> 40

Essential amino acids (EAA)

Intervention Type DIETARY_SUPPLEMENT

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Non-sarcopenic obese

Age: 70-80 years Men, ALM/W \> 25.7 %, body fat % \> 35 Women, ALM/W \> 19.7 %, body fat % \> 40

Essential amino acids (EAA)

Intervention Type DIETARY_SUPPLEMENT

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Non-sarcopenic lean

Age: 70-80 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32

Essential amino acids (EAA)

Intervention Type DIETARY_SUPPLEMENT

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Young lean

Age: 18-40 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32

Essential amino acids (EAA)

Intervention Type DIETARY_SUPPLEMENT

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Essential amino acids (EAA)

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body fat % in accordance with previously defined criteria
* Free of smoking (since 10 years)
* Able to walk without assistance
* Able to perform bilateral leg extension exercise

Exclusion Criteria

* History of or present disease of myocardial, vascular, endocrine, hepatic, renal, pulmonary or neuromuscular origin
* Uncontrolled hypo/hypertension
* Use of anticoagulants (Warfarin, Trombyl)
* Use of metformin or other anti-diabetic medications
* Poor appetite and unexplained weight loss (4,5 kg) over the past 6 months
* Active malignancy
* Present infection
* Dementia or delirium
* Other conditions that may interfere with the study protocol in the opinion of the PI
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Swedish School of Sport and Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

William Apro

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Apró, PhD

Role: PRINCIPAL_INVESTIGATOR

The Swedish School of Sport and Health Sciences and Karolinska Institute, Stockholm Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Swedish School of Sport and Health Sciences

Stockholm, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

William Apró, PhD

Role: CONTACT

Phone: 08-120 538 67

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Oscar Horwath, MSc

Role: primary

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-04016

Identifier Type: -

Identifier Source: org_study_id